Analytical method development and validating the estimation of pregabalin in bulk and its formulation using RP-HPLC
International Journal of Pharmaceutical Research, ISSN: 0975-2366, Vol: 12, Issue: 4, Page: 3763-3767
2020
- 3Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Captures3
- Readers3
Article Description
Pregabalin is an antiseizure drug that is used to treat neuropathic pain, and as an adjuvant in the partial seizures and GAD. It binds with the alpha delta site with very high affinity in the CNS. Though the mechanism of the drug is unknown, results suggested that it binds to the alpha receptors in genetically modified mice and other anticonvulsive models. It is often misused and classified as a Schedule V drug in the U.S. There had been a rapid increase in the number of drugs that are adding to each class of drugs. These drugs are formulated into newer formulations either in a single or multi-drug dosage forms. These newer marketed formulations demand a new investigation for the estimation of the drug in the formulations. The existing analytical techniques for those drugs are available in the research literature, but not all the methods are stable and economical to use. Few other methods are time-consuming too. The objective of this work was to develop an analytical RP-HPLC method for the estimation of Pregabalin in bulk and tablet formulation. RP-HPLC analysis of the drug satisfies the peak integrity, suitability, recovery of the drug. LOQ and LOD of the drug were achieved with high sensitivity. The data shows the precision of the method and the accuracy of the method. Overall, the data suggest that the proposed analytical method can be used to analyze the drug in the formulation. This method can be recommended for the routine analysis of the drug in its dosage form.
Bibliographic Details
SynthesisHub Advance Scientific Research
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know